-
Transporters in Pathophysiology and Toxicity
Wednesday, November 14
2:00 pm – 4:30 pm
Symposium
ACPE #073-999-07-548-L04
Both efflux and uptake membrane-associated transporters affect the pharmacological and toxicological behavior of many drugs and toxins. In the past decade, the clinical development of a number of drug candidates has been discontinued due to unacceptable pharmacokinetic properties and/or toxicity that were not predicted in the preclinical testing of the molecule. The role of transporters in the pharmacokinetics and disposition of molecules and their metabolites has been an area of intense study. However, the clinical significance of these proteins in maintaining normal homeostasis and their relevance to disease etiology are just beginning to emerge. In several pathological conditions, the expression level and role of membrane drug transporters can be difficult to predict. For example, diseases such as epilepsy or HIV infection and/or conditions associated with cytokine release are well known to modulate P-gp expression and function. The objectives of this symposium are to discuss recent findings that highlight the importance of drug transporters as genetic modifiers in physiopathology and toxicity.
Moderators
Yurong Lai, Ph.D.
Pfizer, Inc.
Introduction
Yurong Lai, Ph.D.
Pfizer, Inc.
Role of Hepatobiliary Transporters in Drug-induced Liver Disease
Gerd Kullack-Ublick, Ph.D.
University Hospital
Role of PEPT2 in Protecting the Brain from Neurotoxic Substances
David E. Smith, Ph.D.
University of Michigan
Regulation of P-glycoprotein by HIV-1 Inflammatory Response
Reina Bendayan, Pharm.D.
University of Toronto
Contributed Papers Presentation
Speech Title and
Speaker to be Announced